Tilray to Collaborate With Sandoz on Medical Cannabis Products Across the World
Tilray Inc. announced Tuesday that its Tilray Canada Ltd. subsidiary has entered into a global “framework agreement” to collaborate with Sandoz AG, part of Novartis group, to increase availability of high quality medical cannabis products across the world. Shares of Tilray were surging in Tuesday afternoon trading after the announcement. Under the deal, Tilray and Sandoz’s Canadian arm plan…
Outlook 2019: Tech, Data, and Biotech Boom
Digitalization, automation, artificial intelligence (AI), enhanced data analysis, and a growing trend toward more personalized products will be among the hottest pharmaceutical developments in 2019, according to industry experts. Such modern trends may be common for most industries, but pharma traditionally has been slow to accept change, partly due to cost factors and largely due…
CDMO Recipharm Partnership Aims to Advance ADHD Treatment in U.S. Market
CDMO Recipharm has entered into an agreement with Swedish life science company OnDosis for the formulation development of a treatment for attention deficit hyperactivity disorder (ADHD) in the U.S. market. Although there is no cure for ADHD, currently available treatments may help reduce symptoms and improve functioning, according to the National Institute of Mental Health (NIMH). ADHD is commonly treated…
Merck’s Global Human Health President Schechter Leaving at End of Year
O’Day Leaving Roche for Gilead; Genentech’s Anderson Taking Over at Roche
Major leadership changes at two of the world’s top pharmaceutical companies were announced today. Daniel O’Day, currently chief executive officer of Roche Pharmaceuticals and member of its corporate executive committee, will be joining Gilead Sciences, Inc. as chairman and CEO starting March 1. His exit from the Roche Pharmaceuticals helm is effective December 31, but he will stay on…
FDA Drug Shortages and Discontinuations: 12/10/18 Update
FDA Drug Shortages: 12/3/18 Update
Bayer Shedding 12,000 Jobs, Exiting Animal Care Business
In a strategic move, Bayer plans to cut as many as 12,000 jobs over the next few years, shed its animal care business, and exit from the Coppertone and Dr. Scholl’s consumer product lines. Most of the job cuts will come from operations in Germany, according to the company, which employs some 118,000 workers globally. Bayer…
Leadership Roles Are Scarce for Women in Big Pharma
While data from “Women in STEM workforce 2017” indicate that 42 percent of science professionals are female, the number of women in executive leadership positions in Big Pharma “dropped depressingly low,” according to a report by U.K.-based Assured Pharmacy, which noted that of the top 10 pharmaceutical companies, only one has a female CEO—Emma Walmsley of GlaxoSmithKline. To classify the number of women in leadership…